FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2338435191> ?p ?o ?g. }

• W2338435191 abstract "Background Despite aspirin-LMWH combination, 10-15% of APS experience pregnancy losses and constitute the refractory obstetrical APS. Methods We analyzed the outcome of pregnancies treated by hydroxychloroquine in patients with APS or asymptomatic antiphospholipid antibodies (aPL) carriers in European study. Results Thirty patients with APS with 35 pregnancies treated by hydroxychloroquine were analyzed. Comparing the outcome of pregnancies treated by the addition of hydroxychloroquine to previous pregnancies under the conventional treatment, pregnancy losses decreased from 81% to 19% (p Among all 30 APS patients, thirteen patients with isolated obstetrical APS (primary APS in 12 cases) experienced 14 pregnancies under hydroxychloroquine. Among them, 5/14 experienced before hydroxychloroquine-treated pregnancy foetal losses or early preeclampsia without any treatment, and 9/14 experienced previous pregnancies losses with aspirin and/or LMWH. After the addition of hydroxychloroquine (400 mg/day [200-400]), the pregnancies losses decreased from 12/14 (86%) to 4/14 (29%) (p Six APL carriers, with associated autoimmune disease in 3 cases (rheumatoid arthritis, undifferentiated connective tissue disease and Sjogren9s syndrome) experienced 10 pregnancies under hydroxychloroquine (with median amount 200 mg/day [200-400]). Among the 10 pregnancies under hydroxychloroquine, associated treatments were used in all cases (aspirin alone in 6 cases, aspirin-LMWH and aspirin with prednisone in 2 cases each) and 8 (80%) resulted in live-born babies. Five patients with purely thrombotic APS (undifferentiated connective tissue disease in 2 cases) experienced 5 pregnancies under hydroxychloroquine. All five pregnancies were treated with aspirin-LMWH and hydroxychloroquine at 200 mg/day [200-400] and all resulted in live-born babies. Six patients with primary mixed APS (thrombotic and obstetrical APS) experienced 6 pregnancies under hydroxychloroquine (median amount 400 mg/day [200-400]). Five patients have previous pregnancies with aspirin-LMWH which all resulted in pregnancies losses. All pregnancies after the addition of hydroxychloroquine resulted in 6 live-born babies. Considering 14 patients with previous refractory obstetrical APS (n=5 with obstetrical and thrombotic primary APS and n=9 with purely obstetrical APS), all with previous pregnancies losses under treatment (aspirin with LMWH in 11 cases and LMWH in 3 cases), the addition of hydroxychloroquine resulted in live born babies in 11/14 (78%) cases (p Conclusions Our study shows the benefit of hydroxychloroquine addition in patients with refractory obstetrical APS and raises the need of prospective studies to confirm our preliminary study. Acknowledgements We thank European Forum on Antiphospholipid Antibodies and SNFMI Disclosure of Interest None declared" @default.
• W2338435191 created "2016-06-24" @default.
• W2338435191 creator A5008751449 @default.
• W2338435191 creator A5010318952 @default.
• W2338435191 creator A5012091746 @default.
• W2338435191 creator A5012844575 @default.
• W2338435191 creator A5013995263 @default.
• W2338435191 creator A5014840592 @default.
• W2338435191 creator A5027134318 @default.
• W2338435191 creator A5034696952 @default.
• W2338435191 creator A5038341647 @default.
• W2338435191 creator A5041077575 @default.
• W2338435191 creator A5061119590 @default.
• W2338435191 creator A5067041568 @default.
• W2338435191 creator A5070086032 @default.
• W2338435191 creator A5073717582 @default.
• W2338435191 creator A5075211914 @default.
• W2338435191 creator A5076209873 @default.
• W2338435191 creator A5079447134 @default.
• W2338435191 creator A5082019271 @default.
• W2338435191 creator A5087386909 @default.
• W2338435191 date "2015-06-01" @default.
• W2338435191 modified "2023-09-25" @default.
• W2338435191 title "THU0396 The Efficacy of Hydroxychloroquine for Obstetrical Outcome in Anti-Phospholipid Syndrome: Data from a European Multicenter Retrospective Study" @default.
• W2338435191 doi "https://doi.org/10.1136/annrheumdis-2015-eular.1716" @default.
• W2338435191 hasPublicationYear "2015" @default.
• W2338435191 type Work @default.
• W2338435191 sameAs 2338435191 @default.
• W2338435191 citedByCount "0" @default.
• W2338435191 crossrefType "journal-article" @default.
• W2338435191 hasAuthorship W2338435191A5008751449 @default.
• W2338435191 hasAuthorship W2338435191A5010318952 @default.
• W2338435191 hasAuthorship W2338435191A5012091746 @default.
• W2338435191 hasAuthorship W2338435191A5012844575 @default.
• W2338435191 hasAuthorship W2338435191A5013995263 @default.
• W2338435191 hasAuthorship W2338435191A5014840592 @default.
• W2338435191 hasAuthorship W2338435191A5027134318 @default.
• W2338435191 hasAuthorship W2338435191A5034696952 @default.
• W2338435191 hasAuthorship W2338435191A5038341647 @default.
• W2338435191 hasAuthorship W2338435191A5041077575 @default.
• W2338435191 hasAuthorship W2338435191A5061119590 @default.
• W2338435191 hasAuthorship W2338435191A5067041568 @default.
• W2338435191 hasAuthorship W2338435191A5070086032 @default.
• W2338435191 hasAuthorship W2338435191A5073717582 @default.
• W2338435191 hasAuthorship W2338435191A5075211914 @default.
• W2338435191 hasAuthorship W2338435191A5076209873 @default.
• W2338435191 hasAuthorship W2338435191A5079447134 @default.
• W2338435191 hasAuthorship W2338435191A5082019271 @default.
• W2338435191 hasAuthorship W2338435191A5087386909 @default.
• W2338435191 hasConcept C126322002 @default.
• W2338435191 hasConcept C131872663 @default.
• W2338435191 hasConcept C141071460 @default.
• W2338435191 hasConcept C2776874634 @default.
• W2338435191 hasConcept C2777218350 @default.
• W2338435191 hasConcept C2777575956 @default.
• W2338435191 hasConcept C2777628954 @default.
• W2338435191 hasConcept C2779123688 @default.
• W2338435191 hasConcept C2779134260 @default.
• W2338435191 hasConcept C2779234561 @default.
• W2338435191 hasConcept C2780868729 @default.
• W2338435191 hasConcept C3008058167 @default.
• W2338435191 hasConcept C524204448 @default.
• W2338435191 hasConcept C54355233 @default.
• W2338435191 hasConcept C71924100 @default.
• W2338435191 hasConcept C86803240 @default.
• W2338435191 hasConceptScore W2338435191C126322002 @default.
• W2338435191 hasConceptScore W2338435191C131872663 @default.
• W2338435191 hasConceptScore W2338435191C141071460 @default.
• W2338435191 hasConceptScore W2338435191C2776874634 @default.
• W2338435191 hasConceptScore W2338435191C2777218350 @default.
• W2338435191 hasConceptScore W2338435191C2777575956 @default.
• W2338435191 hasConceptScore W2338435191C2777628954 @default.
• W2338435191 hasConceptScore W2338435191C2779123688 @default.
• W2338435191 hasConceptScore W2338435191C2779134260 @default.
• W2338435191 hasConceptScore W2338435191C2779234561 @default.
• W2338435191 hasConceptScore W2338435191C2780868729 @default.
• W2338435191 hasConceptScore W2338435191C3008058167 @default.
• W2338435191 hasConceptScore W2338435191C524204448 @default.
• W2338435191 hasConceptScore W2338435191C54355233 @default.
• W2338435191 hasConceptScore W2338435191C71924100 @default.
• W2338435191 hasConceptScore W2338435191C86803240 @default.
• W2338435191 hasLocation W23384351911 @default.
• W2338435191 hasOpenAccess W2338435191 @default.
• W2338435191 hasPrimaryLocation W23384351911 @default.
• W2338435191 isParatext "false" @default.
• W2338435191 isRetracted "false" @default.
• W2338435191 magId "2338435191" @default.
• W2338435191 workType "article" @default.